LIVERATION trial: a multicentre European randomised study on radiofrequency margin coagulation and its impact on oncological outcomes after liver surgery - study protocol.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luque Villalobos Eduardo, Ielpo Benedetto, Aldrighetti Luca, Anselmo Alessandro, Beghdadi Nassiba, Berardi Giammauro, Briceño Francisco, Ciria Ruben, Dorcaratto Dimitri, Durczynski Adam, Ettorre Giuseppe Maria, Delvecchio Antonella, Ferri Valentina, Grąt Michał, Garces-Albir Marina, Grochola Lukasz Filip, Hogendorf Piotr, Izzo Francesco, Kobryn Konrad, Kontis Elissaios, Korkolis Dimitris, Król Robert, Lesurtel Mickael, Lopez-Ben Santiago, Christogiannis Christos, Koutsiouroumpa Ourania, Mavridis Dimitris, Memeo Riccardo, Murawa Dawid, Machairas Nikolaos, Mora-Oliver Isabel, Muñoz-Forner Elena, Orrego Carola, Dantas Carina, Fuste Carlos, García Picazo Alberto, Pessaux Patrick, Pilat Tomasz, Pittau Gabriella, Radosevic Aleksandar, Ratti Francesca, Sotiropoulos Georgios, Toutouzas Konstantinos, Trotovsek Blaz, Wystrychowski Wojciech, Zacharoulis Dimitris, Vicente Emilio, Burdio Fernando, Sánchez Velázquez Patricia
Аннотация
METHODS AND ANALYSIS: The LIVERATION trial is an international, multicentre, single-blind, randomised, parallel-group, controlled clinical trial involving 698 patients undergoing liver resection for CRLM or HCC. Participants will be randomly assigned in a 1:1 ratio to either AMC (study group) or conventional liver resection (control group) to assess oncological outcomes for both CRLM and HCC. The primary outcome is the incidence of LR. Secondary endpoints include overall survival, disease-free survival, cancer-specific survival, surgical complications and quality of life. Follow-ups occur at 30 days, 90 days, and 1, 2 and 3 years postoperatively.
ETHICS AND DISSEMINATION: The LIVERATION trial has been approved by the Ethics Committee at the sponsor site Hospital del Mar de Barcelona, CEIM-PSMAR (Comité de Ética de la Investigación con Medicamentos - Parc de Salut Mar), as well as by the Institutional Ethics Committees in all participating countries. The results of the main trial, along with each of the secondary endpoints, will be submitted for publication in a peer-reviewed journal. The study adheres to national and international guidelines, including the Declaration of Helsinki, and complies with regulations for studies involving biological samples under Law 14/2007 on Biomedical Research. A dissemination strategy has been developed to engage stakeholders and facilitate knowledge transfer to support the use of the findings of the study. LIVERATION is funded by the European Union under the Horizon Europe Framework Programme (Project Number: 101104360).
TRIAL REGISTRATION NUMBER: NCT05492136.